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Abstract
Oxytocin has been suggested as a promising new treatment for neurodevelopmental disor-
ders. However, important gaps remain in our understanding of its mode of action, in particu-
lar, to what extent oxytocin modulates social and non-social behaviours and whether its
effects are generalizable across both sexes. Here we investigated the effects of a range of
oxytocin doses on social and non-social behaviours in C57BL/6N mice of both sexes. As
the striatum modulates social and non-social behaviours, and is implicated in neurodeve-
lopmental disorders, we also conducted a pilot exploration of changes in striatal protein
expression elicited by oxytocin. Oxytocin increased prepulse inhibition of startle but attenu-
ated the recognition memory in male C57BL/6N mice. It increased social interaction time
and suppressed the amphetamine locomotor response in both sexes. The striatum prote-
ome following oxytocin exposure could be clearly discriminated from saline controls. With
the caveat that these results are preliminary, oxytocin appeared to alter individual protein
expression in directions similar to conventional anti-psychotics. The proteins affected by
oxytocin could be broadly categorized as those that modulate glutamatergic, GABAergic or
dopaminergic signalling and those that mediate cytoskeleton dynamics. Our results here
encourage further research into the clinical application of this peptide hormone, which may
potentially extend treatment options across a spectrum of neurodevelopmental conditions.
Introduction
Oxytocin has a recognised role in lactation and parturition. However, it also has central bind-
ing sites in the limbic system and basal ganglia [1] and is now appreciated to be involved in the
regulation of a wide variety of social and non-social behaviours [2]. As a consequence, oxytocin
has been proposed to have utility in neurodevelopmental disorders of social processing and
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cognition. Emerging evidence suggests oxytocin can serve as an antipsychotic that modulates
glutamatergic signalling [3]. Indeed, several studies have reported that oxytocin ameliorated
symptoms of schizophrenia [4] and exerted a generally positive impact on social behaviour,
cognition and memory in humans [5].
Preclinical studies are broadly in agreement. Social interaction deficits in rats caused by
chronic phencyclidine administration were reversed by oxytocin [6] and rats treated with anti-
psychotics had elevated oxytocin secretion, suggesting that endogenous oxytocin contributes to
the antipsychotic action of conventional antipsychotic drugs [3]. However, there remain a
number of gaps in our understanding of oxytocin’s therapeutic potential. First, pre-clinical
studies often examine a limited range of behavioural tasks, and it is unclear whether oxytocin
modulates both social and non-social behaviours at the doses used. Second, many studies have
a male bias but, since brain oxytocin and oxytocin receptor distributions are sex specific [7], it
is not known if results generalize across both sexes. Third, the protein substrates in the neural
networks targeted by oxytocin remain relatively obscure. Therefore, in this study we sought to
clarify the effects of a range of oxytocin doses on social and non-social behaviours in female
and male C57BL/6N mice. We hypothesized that peripherally injected oxytocin would improve
performance in social and non-social tasks and alter protein expression in a similar direction
to that reported for anti-psychotic medication.
We also predicted that oxytocin would alter protein expression in brain. We selected the
striatum as a region-of -interest because it is a major neural substrate of oxytocin [8]; it is
strongly implicated in neurodevelopmental disorders [9], linked to both social and non-social
behaviour traits in these conditions [10]. For example, neuroanatomical differences relative to
typically developing controls are consistently reported in autism and schizophrenia [11–14]. In
line with this, preclinical studies have linked the striatum to behaviors relevant to these disor-
ders including sensorimotor gating, social interaction and amphetamine sensitivity [15–21]. In
addition, the striatum is considered to be a key target for the anti-psychotic action of medica-
tions used in schizophrenia [22–27]. Therefore, we predicted that oxytocin would alter striatal
protein expression a similar direction to that reported in preclinical and clinical studies of con-
ventional anti-psychotic treatment.
Materials and Methods
Animals
One hundred and sixteen adult C57BL/6N mice (8 weeks old, female = 58, male = 58) were
used in this study of oxytocin. All mice were obtained from and housed in the Laboratory Ani-
mal Unit (LAU) at the University of Hong Kong. The experimental protocol had been
approved by the Committee on the Use of Live Animals for Teaching and Research, the Uni-
versity of Hong Kong (CULATR case no: 2189–10, 2624–12). The behaviour holding room
was maintained at 21°C but, unlike the general areas of the LAU, had a reversed day-night
cycle (light on: 7PM-7AM). Mice were therefore acclimatized for a minimum of one week
before testing. All behavioural tests were conducted in the dark phase of the light-dark cycle.
Behavioural testing
Prepulse inhibition test (PPI). The whole-body startle responses of mice were measured
in mouse startle chambers supplied by SR-LAB (San Diego Instruments, San Diego, CA, USA).
Mice were placed in the startle chamber immediately after either oxytocin or saline injection
and left undisturbed for 10min before the PPI test began [28]. The PPI paradigm conducted
followed the standard protocol in our lab [29]. As pharmacological treatments can alter base-
line reactivity to startle stimuli, and confound interpretation of the PPI [30], for this paradigm
Oxytocin Effects on Behaviour and Protein Expression in C57BL/6N Mice
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we employed a design incorporating 3 prepulse and 3 pulse conditions [31]. This allowed us to
exclude conditions where altered baseline reactivity might confound interpretation of PPI. All
startle stimuli and background stimuli (NS) comprised white noise. The background stimulus
was 65dB. The three intensities of a 40ms pulse were 100dB, 110dB and 120dB; the three 20ms
prepulse intensities were 6dB, 12dB or 18dB above background. The session began with six
consecutive pulse-alone trials. The first block (first six trials) had two of each pulse-alone con-
dition to habituate and stabilize the startle response. These trials were not included in the sta-
tistical analysis. Thereafter the test session included 10 blocks of 16 trials in pseudorandom
order. Each block was composed of three prepulse-alone trials (+6, +12 or +18dB), three pulse-
alone trials (100, 110 or 120dB), 9 combinations of prepulse-pulse trials (3 prepulse options×3
pulse options), and one no-stimulus (NS) trial. The test session ended with a final block of six
pulse-alone trials as in the first block. The whole session lasted approximately 45 minutes.
PPI data were collected by SR-LAB. PPI was taken as the reduction in pulse-induced startle
reaction on prepulse_pulse trials relative to the reaction in the pulse_alone trials. The propor-
tional (percentage) reduction of the startle amplitude (%PPI) based on the non-transformed
startle response was calculated by the formula [(Rpulse_alone—Rprepulse_pulse)/ Rpulse_
alone] × 100%, where “R” was the individual mean response of the startle reaction. PPI data
were analysed by repeated measures ANOVA, with pulse intensity (100 110 or 120 dB) and
prepulse intensity (+6, +12 or +18 dB) as within-subject factors, and drug dose (saline and
three doses of oxytocin), sex and drug exposure (single or repeated dose), as between-subject
factors. Data are presented as (Mean ± SEM) and were analysed with IBM SPSS 22.0 software.
P values less than 0.05 were considered to indicate statistical significance.
Novel object recognition test. Object recognition in mice followed a standard protocol
[32]. Mice were placed into an open field (40 cm×40 cm) test box, in which two identical solid
impermeable objects (A1, A2) were positioned at one end of the field, each 10cm from the adja-
cent walls. Mice were allowed to explore the area for 3mins (Exploration Session-1). One hour
later, they were exposed to the same open field and objects, which had been thoroughly cleaned
with 70% ethanol, for 3 mins (Exploration Session-2). Either oxytocin or saline was adminis-
tered immediately after the second exploration session. After 24 hours, the mice were again
exposed to the test apparatus this time containing one of the original objects (A2) and a novel
object (B) (different size, shape and colour, Fig 1). The time spent exploring each of the objects
(Exploration Session-3) was assessed over 3 min.
A discrimination index was calculated as the (exploration of novel object-exploration of
familiar object)/ (total exploration time), i.e. (B-A2)/ (B+A2). All the mice had received one
previous dose of drug injection respectively before the novel object recognition test. Recogni-
tion memory was assessed by the discrimination index. The novelty discrimination index was
analysed using a two-way ANOVA, SPSS22, with sex and drug dose as between-subjects
factors.
Social interaction test
The social interaction test was carried out in a neutral cage with standard bedding (30 cm×30
cm×30 cm) following methods previously published [33]. On the first three days before the
test, each mouse, including mice of the same strain, age and sex to be used as ‘strangers’, were
habituated to the cage in one 10min session each day. On day 4, the test day, either oxytocin or
saline was administered 30min before the test. Pairs of an unfamiliar, ‘stranger’mouse and
experimental mouse were placed into the neutral cage for 10 min. The time spent in social
interaction (active contact such as sniffing, following and grooming the partner) was measured
over 10 min.
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The effects of oxytocin dose and exposure were analysed using a Univariate General Linear
Model (GLM, SPSS 22), in which the drug dose and exposure (single or repeated) were the
between-subject factors.
Open field and amphetamine test
The open field exploration test was tested following methods previously published [34]. It was
performed in 40×40 cm2 rectangular white arenas. At the beginning of the session, the mouse
was gently placed in the centre of the arena, and allowed to explore for 1hour while drug free.
The mouse was then briefly removed from the arena, and drug administered quickly via the
subcutaneous (s.c.) route. The arena was cleaned with 70% ethanol; the mouse was placed back
in the arena and allowed to explore for another 30min. The mouse was again briefly removed
from the arena and injected with 2.5 mg/kg d-amphetamine (calculated as the salt, sigma-
Aldrich, Switzerland) dissolved in a 0.9% NaCl solution via the intraperitoneal route. The vol-
ume of injection was 5 ml/kg. The arena was cleaned again. The mouse was placed back in the
arena and allowed to explore for another 1hour (Fig 2).
Order of behavioural testing
Equal numbers of male and female mice received a single subcutaneous dose of 10 μg/kg,
100 μg/kg or 1000 μg/kg of oxytocin (Sigma Chemicals, St Louis, Mo., USA) in an injection vol-
ume of 5 ml/kg prior to testing. All mice were given one week of ‘rest’ between each test. Each
mouse received the same dose of oxytocin or saline for all tests. To control for the potential
effect of previous oxytocin exposure and/or behavioural test order, half the mice followed test
sequence I; half followed test sequence II (Fig 3). Twenty mice (10 females; 10 males) received
Fig 1. Novel object recognition test. Blue circles: A1, A2; original objects. Red triangle: B; novel object.
Oxytocin doses: 10 μg/kg, 100 μg/kg and 1000 μg/kg. In the first day of the test, the subject explored the two
objects of same colour and same shape twice in 1 hour interval. Oxytocin was administrated in the second
test day, then the subject explored one of the same objects previously presented and a new object of different
colour and shape.
doi:10.1371/journal.pone.0145638.g001
Fig 2. Open field and Amphetamine test.Oxytocin doses: 10 μg/kg, 100 μg/kg and 1000 μg/kg. The
subject explored the arena for 1 hour while drug free. Then the subject explored the same arena for another
30min after drug (saline or oxytocin) injection. Finally the subject explored the same arena again for 1hour
after amphetamine injection.
doi:10.1371/journal.pone.0145638.g002
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saline injections only. There were 32 mice (16 females; 16 males) in each oxytocin dose group:
10 μg/kg, 100 μg/kg or 1000 μg/kg. Where appropriate, whether this was the first exposure to
oxytocin or a repeat exposure was entered as a fixed factor in the analyses.
The open-field and amphetamine challenge test were carried out last; therefore, all animals
had previously received 3 doses of oxytocin or saline. In this test, to clarify whether pre-expo-
sure to oxytocin was sufficient to modify low-dose (2.5 mg/kg) amphetamine response, or
whether an additional dose of oxytocin was necessary, half the cohort received saline immedi-
ately before the amphetamine challenge; half received a single dose of oxytocin (10 μg/kg,
100 μg/kg or 1000 μg/kg)
Proteomics andWestern blot
Twelve mice (female = 6, male = 6) were naïve to behavioural testing; half were exposed to
1000 μg/kg oxytocin, half to saline vehicle injection, once a week for 3 weeks were selected for
proteomics and western blot analysis. The mice were sacrificed by cervical dislocation. The
brain was removed and placed immediately on ice, and the striatum dissected free of the
remainder of the brain tissue. The striatal tissue from each mouse was homogenized in 0.5ml
of ice-cold 0.32 M sucrose buffered with 5 mMHEPES, pH7.5.
Proteomics analyses
Striatum was homogenized in 2D lysis buffer (7M Urea, 2M Thiourea, 2% CHAPS, 10mmol
DTT, 0.5% IPG buffer) for 30 seconds, then centrifuged at 15,000×g for 15 minutes to remove
cell debris. Supernatant for 2-DE was collected and quantified with protein assay kit (Pierce1
660nm Protein Assay, Thermo Scientific).
The 2D procedure followed the protocol from Bio-Rad Laboratories (Bio-Rad Laboratories,
Inc.), with minor modifications. Rehydration and first dimension were carried out using Bio-
Rad isoelectric focusing (IEF) separation (Bio-Rad IEF system). The 350ul rehydration buffer
containing 180ug protein was loaded on 18cm, pH 4–7, IPG DryStrips (Bio-rad). IEF condi-
tions were: 50V, 18h, 1000V, 1h; 3000V, 3h, 8000V, 6h. After the IEF run was complete, the
IPG strips were equilibrated for 2×20min in the equilibration buffer containing 50mM Tris,
6M urea, 30% glycerol, 2% SDS. The first equilibration was performed in the equilibration
buffer with 1.0%w/v DTT followed by a second equilibration with 2.5% w/v iodoacetamide.
Fig 3. Behavioural tests. The sequence of behavioural testing. Mice were dived into two groups of equal
number and sex. Half the mice followed test sequence I; half followed test sequence II. PPI: Prepulse
inhibition of startle.
doi:10.1371/journal.pone.0145638.g003
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The strips were subsequently subjected to a secondary dimensional separation by 12%
SDS-PAGE (Bio-Rad vertical system). The SDS-PAGE was performed at 10mA/gel for 30min,
and then 45mA/gel, until the dye front reached the bottom of gels. After fixing in 50% ethanol,
12% acetate solution and staining with silver nitrate, gels were scanned at 300dpi resolution
and the images were analysed with Image Master Platinum™ software (GE Health care).
Protein spots with p< 0.05 and> 1.3-fold change were considered significant. Spots of
interest were picked from sliver-stained gels, followed by in-gel trypsin digestion and peptide
extraction [35] for protein identification by tandem mass spectrometry analysis using ABI
4800 MALDI TOF/TOF™MS Analyzer (Applied Biosystems, Foster City, CA, USA). The com-
bined peptide mass fingerprinting (PMF) and MS/MS peptide fragmention data were submit-
ted to the NCBInr database and SwissProt database using the software MASCOT version 2.2
(Matrix Science). For all significant protein identifications, both protein and total ion scores
were above or equal to C.I. 99%.
Western blot analyses
The striatum was homogenized at 4°C in lysis buffer (1:5,wt/vol) containing 1mM EDTA and
20mM phenylmethylsulphonyl fluoride. The proteins from the resultant supernatant were
determined (Bio-Rad Protein Assay) for Sodium Dodecyle-Sulphate Polyacrylamide gel elec-
trophoresis (SDS-PAGE). Protein (20ug/lane) was subjected to electrophoresis on a 10% (wt/
vol) polyacrylamide gel in SDS, and gels subsequently processed for electroblotting to polyvi-
nylidene difluoride (PVDF) membranes. The blotted PVDF membranes were saturated with
5% (wt/vol) of skimmed milk in Tris Buffer Saline, PH 7.4 and 0.1% (vol/vol) of Tween 20 for
1h at room temperature. The membranes were sequentially incubated with primary antibodies
to anti-Calcineurin B (rabbit polyclonal IgG antibody, 1:500 dilution, Cat# ab136526, Abcam);
anti-GAD 67 (rabbit polyclonal IgG antibody, 1:1000 dilution, Cat# ab52249, Abcam) and
anti-GAD 65 (rabbit polyclonal IgG antibody, 1:500 dilution, Cat# ab75750, Abcam) overnight
at 4°C following by a peroxidase-labelled anti-mouse/rabbit IgG (1:2000 dilution, Boehringer
Mannheim, Germany) for 1h at room temperature. After thorough washing, positive bands
were revealed using ECL western blotting detection reagents and autoradiography film (Amer-
sham, Biosciences, UK). The intensities of the bands were quantified using IMAGE QUANT
software (Molecular Dynamics, USA).
Statistics
Behavioural results from each task were analysed using a GLM running in SPSS22 with ‘Dose’
of drug (saline, 10 μg/kg, 100 μg/kg, 1000 μg/kg oxytocin), ‘Sex’ and ‘Repeat exposure’ to oxyto-
cin/saline (where appropriate) as between subject factors. Where there was a significant main
effect of Sex, data were analysed in each Sex separately. If there was no effect of repeat expo-
sure, data were combined for further analyses. Significant findings observed using GLM were
explored using post-hoc Bonferroni tests were appropriate.
In PPI, drug treatment may alter the baseline startle response to pulse stimuli. This impacts
upon subsequent analysis of %PPI [30]. Therefore, our PPI design included 3 different pulse
conditions so that, should baseline startle reactivity to any pulse condition be significantly
altered by oxytocin, that pulse condition could be excluded from further analysis of %PPI.
Multivariate analysis using partial least squares-discriminant analysis (PLS-DA, SIMCA
12.0, Umetrics, Umea, Sweden) was performed to examine whether C57BL/6N mice with oxy-
tocin exposure could be discriminated from those with saline exposure on the basis of full pro-
teome profile [36]. Subsequently Analysis of Variance running in the standard in multivariate
data analysis (SIMCA-P+ 12.0, Umetrics) was used to identify proteins with significant up or
Oxytocin Effects on Behaviour and Protein Expression in C57BL/6N Mice
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down regulation in the oxytocin treated group compared to saline treated group. Protein
expression differences in Western Blot were analysed using t-tests.
Results
Behaviour
In saline treated animals, the order of testing had no effect on any test.
Pulse-alone reactivity (Baseline startle reaction). There was significant effect of sex on
baseline pulse reactivity (F (3, 100) = 28.883, p = 0.000); and a significant interaction of
sex × dose (F (3, 100) = 4.243, p = 0.007). However, previous oxytocin exposure had no impact
on the baseline startle response (p = 0.214), therefore data from mice exposed to a single or
repeated dose was combined for further analysis in each sex separately. This analysis indicated
that male mice had higher startle responses than females at all doses of oxytocin (p< 0.01 for
each dose).
Post-hoc analyses in each sex subsequently revealed that oxytocin altered startle responsivity
at only one pulse condition in each sex; lowering the startle response at pulse 120 dB stimulus in
females (F (3, 54) = 3.330, p = 0.026, Fig 4A); increasing the startle response at pulse 100 dB in
male mice (F (3, 54) = 4.157, p = 0.010, Fig 4B). Therefore PPI analyses were conducted in each
sex separately and data from pulse 120dB in females and pulse 100dB in males was excluded.
PPI. Previous oxytocin exposure had no impact on PPI (p = 0.957 in females; p = 0.393 in
males), data from mice exposed to a single or repeated dose was combined for further analysis.
Oxytocin attenuated PPI in females (F (3, 54) = 3.546, p = 0.020), especially following 100 μg/
kg (Boneferroni test; p = 0.012, Fig 4C). In males, there was a significant dose x pulse interac-
tion (F (3, 54) = 3.120, p = 0.033); oxytocin improved PPI at pulse 120dB (F (3, 54) = 5.112,
p = 0.003), at all doses (post-hoc Bonferroni tests, p< 0.01 Fig 4D).
Novel object recognition test. Oxytocin increased time spent exploring objects at first
presentation (F (3, 108) = 4.292, p = 0.007), especially at doses of 100 μg/kg and 1000 μg/kg oxy-
tocin (Bonferroni tests: p = 0.017 and p = 0.033 respectively). There was no effect of Sex on this
measure.
Analysis of the novelty discrimination index revealed a significant sex × dose interaction
approached significance (F (3, 108) = 2.628, p = 0.054). Post-hoc analyses in each sex separately
revealed oxytocin did not alter this index in females but disrupted recognition memory in
males (F (3, 54) = 3.869, p = 0.014) at both 100 μg/kg and 1000 μg/kg doses (Bonferroni,
(p = 0.023 and p = 0.019 respectively, Fig 5A).
Social interaction test. Oxytocin increased social interaction (F (3, 100) = 10.914, p = 0.000)
but there were significant interactions of dose with sex (F (3, 100) = 2.827, p = 0.047); exposure
(F (3, 100) = 4.007, p = 0.009); and sex × exposure (F (3, 100) = 3.365, p = 0.022) on this measure.
Social interaction was therefore examined in each sex separately.
Oxytocin increased social interaction time in females (F (3, 50) = 5.281, p = 0.003) and the
dose × previous exposure interaction was significant (F (3, 50) = 4.789, p = 0.005). Single doses
of oxytocin increased social interaction time in females (F (3, 25) = 5.942, p = 0.03). This result
was driven by the 1000 μg/kg dose (post-hoc Bonferroni p = 0.012; Fig 5B). Previous exposure
to oxytocin also increased social interaction time (F (3, 25) = 3.635, p = 0.027), especially at
doses of 10 μg/kg and 100 μg/kg oxytocin (Bonferroni tests: p = 0.034 and p = 0.049 respec-
tively, Fig 5C).
Oxytocin increased social interaction time in male mice (F (3, 50) = 9.779, p = 0.000) regard-
less of pre-exposure. Therefore data from groups exposed to a single or repeated dose of oxyto-
cin were combined. Post-hoc Bonferroni test confirmed that 100 μg/kg oxytocin significantly
increased social interaction time in male mice (p = 0.019, Fig 5D).
Oxytocin Effects on Behaviour and Protein Expression in C57BL/6N Mice
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Open field and amphetamine challenge test
Basal locomotor activity: All mice had been given three doses of oxytocin or saline before the
open field and amphetamine challenge (Fig 3); all had completed PPI, novel object and social
interaction paradigms. The total distance moved in a one-hour open field test provided a mea-
sure of basal exploratory locomotor activity. Following an injection of oxytocin or saline, loco-
motion was measured for 30 minutes. Finally, each animal received 2.5 mg/kg amphetamine
and locomotion measured for 60 minutes.
Previous exposure to oxytocin lowered baseline activity in both sexes (F (3, 100) = 3.649,
p = 0.015), especially at 100 μg/kg (p = 0.009). There was no effect of an additional dose of oxy-
tocin before testing (Fig 6A and 6B).
Amphetamine-induced locomotor activity:Oxytocin significantly attenuated the response
to amphetamine (F (3, 100) = 11.743, p< = 0.001). There was no effect of an additional dose of
oxytocin before testing. As previous oxytocin exposure altered baseline activity, the data were
reanalysed with baseline distance entered as a covariate. This did not alter the pattern of results;
thus differences in baseline activity could not explain attenuation of amphetamine-induced
hyperlocomotion by oxytocin. There was however a significant time × dose × sex interaction in
the amphetamine response (F (33, 1167) = 2.115, p = 0.000), therefore, post-hoc analysis exam-
ined each sex separately.
Fig 4. PPI test. (A) Oxytocin attenuated the baseline startle response to 120dB pulse in female mice. (B) Oxytocin increased the baseline startle response to
100dB pulse in male mice. (C) 100 μg/kg oxytocin attenuated PPI in females. (D) All doses of oxytocin improved PPI in males. Error bars refer to ± SEM.
doi:10.1371/journal.pone.0145638.g004
Oxytocin Effects on Behaviour and Protein Expression in C57BL/6N Mice
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Oxytocin attenuated the response to amphetamine in females (F (3, 54) = 10.477, p = 0.000),
especially at 100 μg/kg (p = 0.033) and 1000 μg/kg doses (p = 0.000, Fig 6C). It also attenuated
the response to amphetamine in males (F (3, 54) = 3.846, p = 0.015), particularly at the highest
dose (1000μg/kg) (p = 0.008, Fig 6D). As 3 repeated weekly doses of 1000ug/kg oxytocin caused
a clear suppression of amphetamine-induced locomotion in both male and female mice, this
dose regime was chosen for the 2D proteomics analysis.
Striatum proteomics
A total of 811 individual protein spots were visualized across 12 gels (saline: n = 3 males, n = 3
females; oxytocin: n = 3 males, n = 3 females). All spots were included in a partial least squares-
discriminant analysis (PLS-DA), which clearly separated protein expression in mice exposed to
oxytocin from saline controls (Fig 7A).
Analysis of covariance confirmed significant drug-related differences in the expression of 15
proteins (Table 1). Western blot analysis of striatal tissue from animals used for behavioural
testing confirmed that a protein identified in 2D proteomics, calcineurin, was significantly low-
ered by oxytocin.
Fig 5. Novel object recognition and social interaction test. (A) 100 μg/kg and 1000 μg/kg oxytocin disrupted recognition memory in males. 1000 μg/kg
single exposure (B) and 10 μg/kg and 100 μg/kg repeated exposure to oxytocin (C) increased social interaction in females. (D) 100 μg/kg oxytocin increased
social interaction in males. Error bars refer to ± SEM. * post-hoc testing: p<0.05.
doi:10.1371/journal.pone.0145638.g005
Oxytocin Effects on Behaviour and Protein Expression in C57BL/6N Mice
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2D-gel results were confirmed by Western blot analysis in a selected target protein, calci-
neurin. In addition, because 2D-gel analysis suggested that oxytocin may act upon GABA-glu-
tamate pathways, we examined the effects of oxytocin on glutamic acid decarboxylase (GAD65
and GAD67) post-hoc. GAD catalyses the conversion of glutamate to GABA, and is a marker
for GABAergic neurons. Both isoforms have been reported to be lower in schizophrenia and
related neurodevelopmental disorders [37] and dopamine inhibits striatal GAD67 [38]. We
expected that an ‘anti-psychotic’ effect of oxytocin would include up-regulation of GAD67 in
striatum of C57BL/6N mice.
In addition, GAD67 expression (but not GAD65) was significantly elevated by oxytocin (Fig
7B and 7C).
Discussion
Oxytocin has been proposed to be a potential treatment for neurodevelopmental conditions. In
this study, peripherally administered oxytocin improved PPI and social interaction in males
and attenuated the response to amphetamine in open field test in both sexes. This adds to an
increasing body of evidence that oxytocin promotes pro-social behaviour and also modulates
non-social behaviour [2].
There were also global differences (PLS-DA analysis) in protein expression elicited by a
1000 μg/kg dose of oxytocin compared to saline. Oxytocin generally, had effects broadly similar
to conventional anti-psychotics (Table 1). The proteins altered by oxytocin could be catego-
rized as those modulating glutamatergic, GABAergic or dopaminergic signalling systems, and
cytoskeleton components. Such expression changes may in part explain the behavioural differ-
ences observed following oxytocin administration.
Fig 6. Open field and amphetamine test. (A) Distances moved in each 5-min time bin at baseline. (B) Total distance moved in 1 hour at baseline. Previous
exposure to oxytocin lowered baseline activity in both sexes. (C) 100 μg/kg and 1000 μg/kg doses of oxytocin significantly suppressed amphetamine activity
in females. (D) 1000μg/kg Oxytocin exposure significantly suppressed amphetamine activity in males. Error bars refer to ± SEM. *post-hoc testing: p<0.05.
doi:10.1371/journal.pone.0145638.g006
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PPI
Deficits in sensorimotor gating measured using PPI are associated with neurodevelopmental
disorders. We selected the C57BL/6N mouse strain for this study because it has lower PPI than
many other in-bred strains [39] and has been suggested to model aspects of schizophrenia [40].
Thus, any improvement elicited by oxytocin should be evident above the low baseline PPI
expected in these animals.
Oxytocin increased PPI in male mice—a direction of effect similar to that reported using
conventional anti-psychotics [41]. This result is partly consistent with previous reports that
high doses of oxytocin (1000μg/kg) improve PPI in male Brown-Norway rats [42] and reverse
PPI deficits induced by NMDA antagonists in rats [28]. However, the sensitivity of rodents to
oxytocin is likely to be species and strain specific [43], and to be dependent upon the parame-
ters of the PPI paradigm [44].
Fig 7. Striatum proteomics and western blot studies. (A) Multivariate analysis: partial least squares—discriminative analysis (PLS-DA) carried out using
SIMCA-P+12.0 software (Umetrics). The striatal protein profile following oxytocin exposure could be clearly differentiated from saline (controls). The XY axis
shows the coordinates of the protein distribution in the partial least squares—discriminative analysis (B) Western blot gel images of target proteins. (C) The
relative expression of the target proteins/β-actin, Columns showmean±SEM (n = 9 for saline exposure; n = 8 for oxytocin exposure). * p<0.05.
doi:10.1371/journal.pone.0145638.g007
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Although oxytocin attenuated PPI in female mice, as can be seen from Fig 4C and 4D, the
levels of PPI in female mice were higher than even males treated with oxytocin. Thus oxytocin
improved a behaviour ‘impaired’ in males, but had limited impact upon behaviour essentially
intact in females. The latter observation fits with clinical evidence that PPI is intact in females
with schizophrenia [45].
Our results contrast with the previous observation that neither oxytocin knockout [3] nor
oxytocin receptor knockout [46] disrupts PPI. Thus, oxytocin is not ‘necessary’ for PPI, but
does alter it. One mechanism for this action may be through the glutamate-GABA system
which contributes to PPI [47] and is thought to be modulated by oxytocin [48]. Consistent
with this, we found that oxytocin down-regulated ornithine aminotransferase, which catalyses
the transamination of ornithine to glutamate [49]; and, up-regulated 14-3-3 protein zeta/delta
(or KCIP-1), involved in GABAB receptor coupling and dopamine D2 receptor inhibition [50].
In addition, oxytocin increased the level of GAD67 which reflects intraneuronal gamma-ami-
nobutyric acid levels [51]. Thus, we speculate that the net effect of oxytocin may be to promote
GABAergic signalling and restrain glutamate and dopamine activity, improving PPI.
Novel object recognition
In the first step of the novel object paradigm, oxytocin increased time spent exploring the
objects, possibly representing an anxiolytic action [52]. However, the novel object component
of this paradigm indexes memory for a familiar object and oxytocin disrupted recognition
memory in males (Fig 3A) without altering this measure in females.
Table 1. Proteins with differences in expression levels following 3 injections of oxytocin 1000 μg/kg or saline, at an interval of 1 week apart.
Spot
No.
Fold
difference
p
value
Protein name NCBI no. Previous reported change
with antipsychotics
33 1.6651 0.0178 protein DJ-1 gi|55741460 Up [74]
34 1.7887 0.0132 ubiquitin carboxyl-terminal hydrolase isozyme L3 gi|
139948802
(No report)
37 1.3999 0.0453 alpha-enolase gi|34784434 Up [75]
42 1.9003 0.0067 D-3-phosphoglycerate dehydrogenase gi|986918 Up [76]
51 1.6083 0.0433 septin-6 isoform 1 gi|
293597553
Up [76]
80 1.8686 0.0174 gamma-enolse gi|7305027 Up [76]
81 2.1161 0.0329 Rho GDP-dissociation inhibitor 1 gi|31982030 Up [77]
95 1.8751 0.0372 14-3-3 protein zeta/delta isoform 1 gi|6756041 Up [77]
100 1.9886 0.0290 dihydrolipoyllysine-residue succinyltransferase component of
2-oxoglutarate dehydrogenase complex, mitochondrial
gi|21313536 (No report)
109 2.0968 0.0490 triosephosphate isomerase, partial gi|1864018 Down [78]
127 2.2133 0.0049 dihydropyrimidinase-related protein 2 gi|40254595 Up [75]
145 1.9783 0.0026 tubulin alpha-1C chain gi|6678469 Up [76]
275 1.9778 0.0273 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha
subunit, isoform 1
gi|
148677501
Up [74]
322 -6.1599 0.0031 ornithine aminotransferase, mitochondrial precursor gi|8393866 (No report)
330 -2.5450 0.0275 calcineurin subunit-B gi|4506025 Down [78]
Fold differences in protein expression in the oxytocin group relative to the saline group are shown in column 2. Column 6 (ﬁnal column) indicates how
changes in protein expression elicited by oxytocin compare to those reposted to follow antipsychotic treatment in post-mortem studies of schizophrenia
and/or rat models (ﬁnal column).
doi:10.1371/journal.pone.0145638.t001
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Again a pro-GABA action may contribute through calcineurin and KCIP-1 regulation of
GABAA and GABAB receptors respectively. In line with this, GABAA [53] and GABAB [54]
agonists impair recognition memory and calcineurin knockout has also been reported to
impair memory in mice [55].
Social interaction
Oxytocin increased social interaction time in both females and males, but the dose response
was sex-dependent (Fig 5B–5D). Oxytocin had a cumulative effect on social interaction in
female mice; whereas previous exposure to oxytocin in males was no different to a single expo-
sure. These facilitatory effects of oxytocin on social interaction are consistent with studies in
oxytocin knock-out mice [56]. As discussed above, it is possible that oxytocin triggered changes
in GABA signalling contribute. For example, GABAA agonists increase social interaction time
in rats, and antagonists do the opposite [57]. No dose of oxytocin used reduced social interac-
tion, ruling out sedative effects.
Open field activity and response to amphetamine
Amphetamine is an indirect-acting dopamine agonist that increases synaptic dopamine;
patients with schizophrenia are particularly vulnerable to amphetamine. Here, oxytocin sup-
pressed amphetamine-induced locomotion in both sexes (even controlling for baseline activity
differences). A possible explanation is that oxytocin promotes GABA-medicated inhibition of
striatal dopamine release [58], and the increased level of GAD67 following oxytocin exposure
points to increased GABAergic inhibitory activity. However, our proteomics results suggest
additional pathways for oxytocin to limit dopamine mechanisms. For example, the 14-3-3 pro-
tein zeta/delta, up-regulated by oxytocin, is known to inhibit PKC [59] and PKC inhibitors
have been shown to block amphetamine-induced dopamine release from rat striatal synapto-
neurosome [60].
The attenuation of the amphetamine response occurred in mice previously exposed to oxy-
tocin, with or without an additional acute dose of oxytocin (Fig 6). This indication that inter-
mittent exposure to oxytocin can have ‘lasting’ effects will be important to explore further in
light of recent evidence that chronic administration of oxytocin may have undesirable effects,
disrupting social bonding in male voles [61].
Effects of oxytocin on other proteins
In addition to actions on the glutamate-GABA systems, oxytocin had other wide-ranging
effects including on proteins involved in cell structure and plasticity—tubulin-α dihydropyri-
midinase-related protein 2 (DRP-2) and D-3-phosphoglycerate dehydrogenase (3-PGDH)
[62–64]; and mitochondrial function—upregulating ATP synthase subunit alpha [65]; DJ-1
[66], and enolase (linked to recovery of cerebral metabolism in patients with schizophrenia
treated with anti-psychotic medication [67]).
Limitations
There are some limitations to our current study. To reduce the number of animals used, we
tested each mouse in every behavioural paradigm design. The order of testing did not impact
upon findings in the animals exposed to saline, and previous exposure to oxytocin did not
influence results of PPI in either sex or social interaction in males. However, previous exposure
was sufficient to suppress the amphetamine response in both sexes and improve social interac-
tion in females. Unfortunately, our study was not designed to test the effect of an acute
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exposure to oxytocin in naïve animals in the amphetamine challenge (without greatly increas-
ing the number of animals used).
The half-life of oxytocin is 10-15min [68], but only about 0.1% of oxytocin can cross the
blood brain barrier [69]. Therefore the effects studied here are most liekly indirect. The timing
of oxytocin administration was challenging to match across tasks. For example, in PPI, as in
other drug studies using this paradigm, oxytocin was administered 10 mins before the task, but
data collected in the task for a further 45 mins. In the social interaction and amphetamine chal-
lenge tests the effects of oxytocin were captured after 30mins. Thus for these tasks the effects of
oxytocin from 30mins would have been captured. However, oxytocin was given after the ‘learn-
ing phase’ of the object recognition task to establish if it had any effect on the consolidation
stage.
We observed subtle sex differences in the oxytocin dose response. However, the study was
not primarily designed to compare sex differences in response to oxytocin. Rather the study
was designed to look at the effects of oxytocin and both male and female animals were
included. This is increasingly recognised as important and the NIH now requires the reporting
of plans for a balance of male and female animals in preclinical studies unless single sex inclu-
sion is specifically warranted [70].
Unfortunately, the underlying differences in baseline behaviours make interpretation diffi-
cult. For example, as previously reported, female C57BL/6N mice had higher levels of PPI than
males [71]. This is not thought to be a consequence of the oestrous cycle which does not alter
PPI and anxiety-related behaviours in female C57BL mice [72]. Male C57BL/6N mice also had
longer social interaction times than female mice (Fig 5B, 5C&5D); possibly meaning they were
less anxious than females. However, in addition to these baseline behavioural differences
between the sexes, the differential response to oxytocin may also be a consequence of sex differ-
ences in expression of oxytocin and its receptors [7] and further work is therefore needed to
clarify sex effects of oxytocin.
We only examined 2D protein differences in the striatum in response to repeated exposure
to 1000 μg/kg oxytocin in naïve animals, and we cannot directly link differences to phenotypic
differences. However, confirmatory Western blot studies carried out using tissue from animals
involved in the behavioural experiments adds weight to the likelihood that the proteins impli-
cated contribute to the behavioural differences observed. Protein expression differs across
brain regions [73] and we do not know if our results generalize across the brain. Nor did we
examine protein expression in each sex separately. However, the PLS-DA suggests the distinct
protein profile in animals exposed to oxytocin and saline involved both sexes and the effects of
oxytocin on social interaction and amphetamine challenge tasks were broadly similar in both
sexes. Lastly, the proteomics approach used here was a standard analysis that does not fully
sample intracellular organelles. The future separation of subcellular fractions would be useful.
Conclusion
Oxytocin significantly improves social and non-social behaviours in an experimental animal
setting. It elicits a pattern of changes in striatal protein expression similar to that triggered by
conventional antipsychotics. We hope that this study encourages further research into the clin-
ical application of this peptide hormone, which may extend treatment options across a spec-
trum of neurodevelopmental conditions.
Acknowledgments
The authors would like to thank the staff of the Laboratory animal Unit in The University of
Hong Kong for their expert assistance with breeding and husbandry. This study was supported
Oxytocin Effects on Behaviour and Protein Expression in C57BL/6N Mice
PLOS ONE | DOI:10.1371/journal.pone.0145638 December 30, 2015 14 / 18
by research funding from the Hong Kong Universities General Research Fund Award to Dr
Grainne McAlonan (HKU 774710) and research funding from National Natural Science Foun-
dation of China to Professor Wang (61327902) and Professor Zhang (81271406). Dr Grainne
McAlonan is a member of the EU-AIMS consortium.
Author Contributions
Conceived and designed the experiments: XZ GMM SEC. Performed the experiments: XZ QL
SL. Analyzed the data: XZ QL SL. Contributed reagents/materials/analysis tools: MZ BBWW
PCS. Wrote the paper: XZWWGMM. Reviewed and approved the final draft manuscript: All
authors.
References
1. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiological
reviews. 2001; 81(2):629–83. PMID: 11274341
2. Lee H-J, Macbeth AH, Pagani JH. Oxytocin: the great facilitator of life. Progress in neurobiology. 2009;
88(2):127–51. doi: 10.1016/j.pneurobio.2009.04.001 PMID: 19482229
3. Caldwell H, Stephens S, Young rW. Oxytocin as a natural antipsychotic: a study using oxytocin knock-
out mice. Molecular psychiatry. 2008; 14(2):190–6. doi: 10.1038/sj.mp.4002150 PMID: 18227836
4. Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, et al. Adjunctive intranasal oxytocin
reduces symptoms in schizophrenia patients. Biological psychiatry. 2010; 68(7):678–80. doi: 10.1016/j.
biopsych.2010.04.039 PMID: 20615494
5. Tomizawa K, Iga N, Lu Y-F, Moriwaki A, Matsushita M, Li S-T, et al. Oxytocin improves long-lasting spa-
tial memory during motherhood through MAP kinase cascade. Nature neuroscience. 2003; 6(4):384–
90. PMID: 12598900
6. Lee PR, Brady DL, Shapiro RA, Dorsa DM, Koenig JI. Social interaction deficits caused by chronic
phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology. 2005; 30
(10):1883–94. PMID: 15798779
7. Carter CS. Sex differences in oxytocin and vasopressin: implications for autism spectrum disorders?
Behavioural brain research. 2007; 176(1):170–86. PMID: 17000015
8. Loth E, Poline J-B, Thyreau B, Jia T, Tao C, Lourdusamy A, et al. Oxytocin receptor genotype modu-
lates ventral striatal activity to social cues and response to stressful life events. Biological psychiatry.
2013.
9. Langen M, Schnack HG, Nederveen H, Bos D, Lahuis BE, de Jonge MV, et al. Changes in the develop-
mental trajectories of striatum in autism. Biological psychiatry. 2009; 66(4):327–33. doi: 10.1016/j.
biopsych.2009.03.017 PMID: 19423078
10. Tricomi E, Rangel A, Camerer CF, O’Doherty JP. Neural evidence for inequality-averse social prefer-
ences. Nature. 2010; 463(7284):1089–91. doi: 10.1038/nature08785 PMID: 20182511
11. Leung M, Cheung C, Yu K, Yip B, Sham P, Li Q, et al. Gray matter in first-episode schizophrenia before
and after antipsychotic drug treatment. Anatomical likelihood estimation meta-analyses with sample
size weighting. Schizophrenia Bulletin. 2011; 37(1):199–211. doi: 10.1093/schbul/sbp099 PMID:
19759093
12. Yu K, Cheung C, Leung M, Li Q, Chua S, McAlonan G. Are bipolar disorder and schizophrenia neuroa-
natomically distinct? An anatomical likelihood meta-analysis. Frontiers in human neuroscience. 2010;4.
13. Cheung C, Yu K, Fung G, Leung M, Wong C, Li Q, et al. Autistic disorders and schizophrenia: related or
remote? An anatomical likelihood estimation. PloS one. 2010; 5(8):e12233. doi: 10.1371/journal.pone.
0012233 PMID: 20805880
14. Kevin KY, Cheung C, Chua SE, McAlonan GM. Can Asperger syndrome be distinguished from autism?
An anatomic likelihood meta-analysis of MRI studies. Journal of psychiatry & neuroscience: JPN. 2011;
36(6):412.
15. Swerdlow N, Geyer M, Braff D. Neural circuit regulation of prepulse inhibition of startle in the rat: current
knowledge and future challenges. Psychopharmacology. 2001; 156(2–3):194–215. PMID: 11549223
16. Peeke HV, Herz MJ. Caudate nucleus stimulation retroactively impairs complex maze learning in the
rat. Science. 1971; 173(3991):80–2. PMID: 4932263
17. Wyers EJ, Peeke HV, Williston JS, Herz MJ. Retroactive impairment of passive avoidance learning by
stimulation of the caudate nucleus. Experimental Neurology. 1968; 22(3):350–66. PMID: 4884398
Oxytocin Effects on Behaviour and Protein Expression in C57BL/6N Mice
PLOS ONE | DOI:10.1371/journal.pone.0145638 December 30, 2015 15 / 18
18. Brenes JC, Rodríguez O, Fornaguera J. Differential effect of environment enrichment and social isola-
tion on depressive-like behavior, spontaneous activity and serotonin and norepinephrine concentration
in prefrontal cortex and ventral striatum. Pharmacology Biochemistry and Behavior. 2008; 89(1):85–93.
19. King-Casas B, Tomlin D, Anen C, Camerer CF, Quartz SR, Montague PR. Getting to know you: reputa-
tion and trust in a two-person economic exchange. Science. 2005; 308(5718):78–83. PMID: 15802598
20. Castner SA, Becker JB. Sex differences in the effect of amphetamine on immediate early gene expres-
sion in the rat dorsal striatum. Brain research. 1996; 712(2):245–57. PMID: 8814899
21. Castner SA, Xiao L, Becker JB. Sex differences in striatal dopamine: in vivo microdialysis and behav-
ioral studies. Brain research. 1993; 610(1):127–34. PMID: 8518920
22. Konradi C, Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobi-
ology of schizophrenia. Biological psychiatry. 2001; 50(10):729–42. PMID: 11720691
23. Pakkenberg H, Fog R, Nilakantan B. The long-term effect of perphenazine enanthate on the rat brain.
Somemetabolic and anatomical observations. Psychopharmacologia. 1973; 29(4):329–36. PMID:
4707024
24. Nielsen EB, Lyon M. Evidence for cell loss in corpus striatum after long-term treatment with a neurolep-
tic drug (flupenthixol) in rats. Psychopharmacology. 1978; 59(1):85–9. PMID: 100820
25. Takeichi M. Electron Microscopic Morphometric Studies on Synaptic Vesicles of Long-Term CPZ-
Administered Rat Striatum. Psychiatry and Clinical Neurosciences. 1985; 39(2):185–92.
26. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM. Expression of brain-derived neurotrophic factor
mRNA in rat hippocampus after treatment with antipsychotic drugs. Journal of neuroscience research.
2003; 71(1):127–31. PMID: 12478621
27. Deng MY, McAlonan GM, Cheung C, Chiu CP, Law CW, Cheung V, et al. A naturalistic study of grey
matter volume increase after early treatment in anti-psychotic naive, newly diagnosed schizophrenia.
Psychopharmacology. 2009; 206(3):437–46. doi: 10.1007/s00213-009-1619-z PMID: 19641900
28. Feifel D, Reza T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating.
Psychopharmacology. 1999; 141(1):93–8. PMID: 9952070
29. Li Q, Cheung C, Wei R, Hui ES, Feldon J, Meyer U, et al. Prenatal immune challenge is an environmen-
tal risk factor for brain and behavior change relevant to schizophrenia: evidence fromMRI in a mouse
model. PloS one. 2009; 4(7):e6354. doi: 10.1371/journal.pone.0006354 PMID: 19629183
30. Csomor PA, Yee BK, Vollenweider FX, Feldon J, Nicolet T, Quednow BB. On the influence of baseline
startle reactivity on the indexation of prepulse inhibition. Behavioral neuroscience. 2008; 122(4):885.
doi: 10.1037/0735-7044.122.4.885 PMID: 18729642
31. Vuillermot S, Weber L, Feldon J, Meyer U. A longitudinal examination of the neurodevelopmental
impact of prenatal immune activation in mice reveals primary defects in dopaminergic development rel-
evant to schizophrenia. The Journal of Neuroscience. 2010; 30(4):1270–87. doi: 10.1523/
JNEUROSCI.5408-09.2010 PMID: 20107055
32. Bevins RA, Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning
task to study'recognition memory'. Nature protocols. 2006; 1(3):1306–11. PMID: 17406415
33. Spruijt BM, Josephy M, Van Rijzingen I, Maaswinkel H. The ACTH (4–9) analog Org2766 modulates
the behavioral changes induced by NMDA and the NMDA receptor antagonist AP5. The Journal of neu-
roscience. 1994; 14(5):3225–30. PMID: 7910205
34. Meyer U, Nyffeler M, Yee BK, Knuesel I, Feldon J. Adult brain and behavioral pathological markers of
prenatal immune challenge during early/middle and late fetal development in mice. Brain, behavior,
and immunity. 2008; 22(4):469–86. PMID: 18023140
35. Wang Y, Lam KS, Lam JB, LamMC, Leung PT, Zhou M, et al. Overexpression of angiopoietin-like pro-
tein 4 alters mitochondria activities and modulates methionine metabolic cycle in the liver tissues of db/
db diabetic mice. Molecular Endocrinology. 2007; 21(4):972–86. PMID: 17213385
36. Karp NA, Griffin JL, Lilley KS. Application of partial least squares discriminant analysis to two-dimen-
sional difference gel studies in expression proteomics. Proteomics. 2005; 5(1):81–90. PMID: 15744836
37. Guidotti A, Auta J, Davis JM, Gerevini VD, Dwivedi Y, Grayson DR, et al. Decrease in reelin and glu-
tamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem
brain study. Archives of general psychiatry. 2000; 57(11):1061–9. PMID: 11074872
38. Caboche J, Vernier P, Julien JF, Rogard M, Mallet J, Besson MJ. Parallel decrease of glutamic acid
decarboxylase and preproenkephalin mRNA in the rat striatum following chronic treatment with a dopa-
minergic D1 antagonist and D2 agonist. Journal of neurochemistry. 1991; 56(2):428–35. PMID:
1824860
39. Crawley J, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N, et al. Behavioral phenotypes of
inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology.
1997; 132(2):107–24. PMID: 9266608
Oxytocin Effects on Behaviour and Protein Expression in C57BL/6N Mice
PLOS ONE | DOI:10.1371/journal.pone.0145638 December 30, 2015 16 / 18
40. Matsuo N, Takao K, Nakanishi K, Yamasaki N, Tanda K, Miyakawa T. Behavioral profiles of three
C57BL/6 substrains. Frontiers in behavioral neuroscience. 2010;4.
41. Vollenweider FX, Barro M, Csomor PA, Feldon J. Clozapine enhances prepulse inhibition in healthy
humans with low but not with high prepulse inhibition levels. Biological psychiatry. 2006; 60(6):597–
603. PMID: 16997001
42. Feifel D, Shilling PD, Belcher AM. The effects of oxytocin and its analog, carbetocin, on genetic deficits
in sensorimotor gating. European Neuropsychopharmacology. 2012; 22(5):374–8. doi: 10.1016/j.
euroneuro.2011.09.004 PMID: 21962914
43. Scott JP. Agonistic behavior of mice and rats: A review. American Zoologist. 1966; 6(4):683–701.
PMID: 4859807
44. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L. Prestimulus effects on human startle reflex in nor-
mals and schizophrenics. Psychophysiology. 1978; 15(4):339–43. PMID: 693742
45. Kumari V, Aasen I, Sharma T. Sex differences in prepulse inhibition deficits in chronic schizophrenia.
Schizophrenia research. 2004; 69(2):219–35.
46. Swonger JM. Prepulse Inhibition of the Startle Reflex in Forebrain Oxytocin Receptor Knockout Mice:
Kent State University; 2011.
47. Takahashi K, Nagai T, Kamei H, Maeda K, Matsuya T, Arai S, et al. Neural circuits containing pallido-
tegmental GABAergic neurons are involved in the prepulse inhibition of the startle reflex in mice. Biolog-
ical psychiatry. 2007; 62(2):148–57. PMID: 17027927
48. Jo Y-H, Stoeckel M-E, Freund-Mercier M-J, Schlichter R. Oxytocin modulates glutamatergic synaptic
transmission between cultured neonatal spinal cord dorsal horn neurons. The Journal of neuroscience.
1998; 18(7):2377–86. PMID: 9502799
49. Wroblewski JT, Blaker WD, Meek JL. Ornithine as a precursor of neurotransmitter glutamate: Effect of
canaline on ornithine aminotransferase activity and glutamate content in the septum of rat brain. Brain
research. 1985; 329(1):161–8.
50. Johnson SW, North RA. Two types of neurone in the rat ventral tegmental area and their synaptic
inputs. The Journal of physiology. 1992; 450(1):455–68.
51. K R, DL M. The level of GAD 67 protein is highly sensitive to small increases in interpersonal gamma-
rainout acid levels. J Neurochem. 1994;Apr; 62(4):1375–81. PMID: 8133268
52. Crawley JN. Exploratory behavior models of anxiety in mice. Neuroscience & Biobehavioral Reviews.
1985; 9(1):37–44.
53. Roberts E. GABA: the road to neurotransmitter status. Benzodiazepine/GABA receptors and chloride
channels: structural and functional properties. 1986:1–39.
54. Castellano C, Brioni JD, Nagahara AH, McGaugh JL. Post-training systemic and intra-amygdala admin-
istration of the GABA-B agonist baclofen impairs retention. Behavioral and neural biology. 1989; 52
(2):170–9. PMID: 2552976
55. Zeng H, Chattarji S, Barbarosie M, Rondi-Reig L, Philpot BD, Miyakawa T, et al. Forebrain-specific cal-
cineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory.
Cell. 2001; 107(5):617–29. PMID: 11733061
56. Ferguson JN, Aldag JM, Insel TR, Young LJ. Oxytocin in the medial amygdala is essential for social
recognition in the mouse. The Journal of Neuroscience. 2001; 21(20):8278–85. PMID: 11588199
57. Shekhar A, Katner J. Dorsomedial hypothalamic GABA regulates anxiety in the social interaction test.
Pharmacology Biochemistry and Behavior. 1995; 50(2):253–8.
58. Scheel-Krüger J. Dopamine-GABA interactions: evidence that GABA transmits, modulates and medi-
ates dopaminergic functions in the basal ganglia and the limbic system. Acta Neurologica Scandina-
vica. 1986.
59. Wheeler-Jones C, Learmonth M, Martin H, Aitken A. Identification of 14-3-3 proteins in human platelets:
effects of synthetic peptides on protein kinase C activation. Biochem J. 1996; 315:41–7. PMID:
8670130
60. Kantor L, Gnegy M. Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat
striatal slices. Journal of Pharmacology and Experimental Therapeutics. 1998; 284(2):592–8. PMID:
9454802
61. Bales KL, Perkeybile AM, Conley OG, Lee MH, Guoynes CD, Downing GM, et al. Chronic intranasal
oxytocin causes long-term impairments in partner preference formation in male prairie voles. Biological
psychiatry. 2013; 74(3):180–8. doi: 10.1016/j.biopsych.2012.08.025 PMID: 23079235
62. Wheal HV, Chen Y, Mitchell J, Schachner M, Maerz W, Wieland H, et al. Molecular mechanisms that
underlie structural and functional changes atthe postsynaptic membrane duringsynaptic plasticity.
Progress in neurobiology. 1998; 55(6):611–40. PMID: 9670221
Oxytocin Effects on Behaviour and Protein Expression in C57BL/6N Mice
PLOS ONE | DOI:10.1371/journal.pone.0145638 December 30, 2015 17 / 18
63. Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N, Honnorat J. Collapsin response mediator
proteins (CRMPs). Molecular neurobiology. 2003; 28(1):51–63. PMID: 14514985
64. Klomp LW, de Koning TJ, Malingré HE, van Beurden EA, Brink M, Opdam FL, et al. Molecular charac-
terization of 3-phosphoglycerate dehydrogenase deficiency—a neurometabolic disorder associated
with reduced L-serine biosynthesis. The American Journal of Human Genetics. 2000; 67(6):1389–99.
65. Fillingame RH. Molecular mechanics of ATP synthesis by F1F0-type H+-transporting ATP synthases.
The bacteria. 1990; 12:345–91.
66. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress
to prevent cell death. EMBO reports. 2004; 5(2):213–8. PMID: 14749723
67. Szechtman H, Nahmias C, Garnett ES, Firnau G, Brown GM, Kaplan RD, et al. Effect of neuroleptics on
altered cerebral glucose metabolism in schizophrenia. Archives of General Psychiatry. 1988; 45
(6):523–32. PMID: 2897836
68. Dawood M. Neurohypophyseal hormones. Endocrinology of Pregnancy, 3rd Edition Philadelphia:
Harper & Row. 1983:204–28.
69. Jones P, Robinson I. Differential clearance of neurophysin and neurohypophysial peptides from the
cerebrospinal fluid in conscious guinea pigs. Neuroendocrinology. 1982; 34(4):297–302. PMID:
7070597
70. Clayton JA, Collins FS. NIH to balance sex in cell and animal studies. Nature. 2014; 509(7500):282–3.
PMID: 24834516
71. Zhang X, Li Q, Wong N, Zhang M,WangW, Bu B, et al. Behaviour and prefrontal protein differences in
C57BL/6N and 129 X1/SvJ mice. Brain research bulletin. 2015.
72. Meziane H, Ouagazzal AM, Aubert L, Wietrzych M, Krezel W. Estrous cycle effects on behavior of
C57BL/6J and BALB/cByJ female mice: implications for phenotyping strategies. Genes, Brain and
Behavior. 2007; 6(2):192–200.
73. Takao K, Kobayashi K, Hagihara H, Ohira K, Shoji H, Hattori S, et al. Deficiency of Schnurri-2, an MHC
enhancer binding protein, induces mild chronic inflammation in the brain and confers molecular, neuro-
nal, and behavioral phenotypes related to schizophrenia. Neuropsychopharmacology. 2013; 38
(8):1409–25. doi: 10.1038/npp.2013.38 PMID: 23389689
74. Clark D, Dedova I, Cordwell S, Matsumoto I. Altered proteins of the anterior cingulate cortex white mat-
ter proteome in schizophrenia. PROTEOMICS-Clinical Applications. 2007; 1(2):157–66. doi: 10.1002/
prca.200600541 PMID: 21136665
75. Pennington K, Föcking M, McManus C, Pariante C, DunnM, Cotter D. A proteomic investigation of simi-
larities between conventional and herbal antidepressant treatments. Journal of Psychopharmacology.
2009; 23(5):520–30. doi: 10.1177/0269881108091075 PMID: 18562437
76. Pennington K, Beasley C, Dicker P, Fagan A, English J, Pariante C, et al. Prominent synaptic and meta-
bolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia
and bipolar disorder. Molecular psychiatry. 2007; 13(12):1102–17. PMID: 17938637
77. Nesvaderani M, Matsumoto I, Sivagnanasundaram S. Anterior hippocampus in schizophrenia patho-
genesis: molecular evidence from a proteome study. Australasian Psychiatry. 2009; 43(4):310–22.
78. RushlowW, Seah Y, Belliveau D, Rajakumar N. Changes in calcineurin expression induced in the rat
brain by the administration of antipsychotics. Journal of neurochemistry. 2005; 94(3):587–96. PMID:
16033416
Oxytocin Effects on Behaviour and Protein Expression in C57BL/6N Mice
PLOS ONE | DOI:10.1371/journal.pone.0145638 December 30, 2015 18 / 18
